EndoCure
EndoCure is transforming an off-the-shelf ultrasound into an AI-enabled, objective, high-res 3D tool
Company Overview
Snapshot
Founded in November 2023 by Hadas Ziso and Moshe Shoham, EndoCure operates with 1-10 employees. The company has raised $2.55 million across 6 funding rounds from 3 investors.
Business overview
EndoCure develops an AI-enabled robotic ultrasound imaging platform, Revealan, designed to improve the accurate diagnosis of chronic conditions like cancer and endometriosis. This technology integrates with existing ultrasound devices to provide operator-agnostic, automated, high-resolution 3D imaging, offering a data density 10 times higher than MRI. EndoCure operates within the Health Tech & Life Sciences sector, specifically targeting medical devices, and serves hospitals, outpatient imaging centers, private clinics, and telemedicine providers.
Strategic signal
In January 2026, EndoCure announced a $700,000 Pre-Seed funding round, bringing its total raised to $2.7 million. This investment, with participation from Teuza VC fund and HiCenter Ventures, is earmarked for achieving FDA clearance and initiating commercialization of its robotic ultrasound platform, Revealan. This signals strong investor confidence in EndoCure's technology and its potential to address critical diagnostic gaps in conditions like endometriosis and cancer, positioning the company for significant market entry and growth in the near future.
Log in to access full profile ›Company Intelligence Q&A
- What is EndoCure's primary product?
- EndoCure's primary product is Revealan, a robotic ultrasound imaging platform that transforms off-the-shelf ultrasound devices into AI-enabled, objective, high-resolution 3D tools for improved diagnostics.
- When was EndoCure founded and by whom?
- EndoCure was founded in November 2023 by Hadas Ziso and Moshe Shoham.
- What was a key funding event for EndoCure in 2026?
- In January 2026, EndoCure raised $700,000 in a Pre-Seed round from investors including Teuza VC fund. These funds are intended for FDA clearance and commercialization.
- What significant recognition did EndoCure receive in November 2023?
- In November 2023, EndoCure was selected as a TOP12 finalist at the MEDICA Startup Competition, out of 280 submissions.
- What is the strategic importance of EndoCure's technology for diagnostics?
- EndoCure's Revealan platform aims to overcome limitations of current imaging tools by providing standardized, high-density 3D images, enabling earlier detection and more reliable follow-ups for conditions like cancer and endometriosis, which are often misdiagnosed.